C. Ola Landgren, M.D., Ph. D. (IMAGE)

University of Miami Miller School of Medicine

C. Ola Landgren, M.D., Ph. D.

Caption

Using MRD as a clinical endpoint “will enable drug approval through a special, accelerated pathway that could shave years off the process,” says C. Ola Landgren, MD, PhD, director of Sylvester’s Myeloma Research Institute, who led the analysis behind a recent FDA committee vote.

Credit

Photo by Sylvester

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.